Advantag of ingestion administration way is its easiness even when applied at home. But with their help necessary treatment concentration in blood cannot be always quickly achieve amoxil online transaction is carried out on anonymity and mutual profit principles, and in addition customers will be positively surprised with quality and speed of service.

Microsoft word - 1383toc

ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY &
Are Antidepressants Totally Safe? A Moot but PRODUCT DEFINITIONS
Manufacturers Vociferous in their Protests.II-13 No Satisfactory Answers Yet – The Wait Grows Longer.II-13 II. EXECUTIVE SUMMARY
Global Antidepressants Market: Drug Regulation for Kids in Britain and the United States .II-13 1. Industry
Overview . II-1
3. Depression: A Mental Review . II-14
Industry Dynamics and Changing Scenario. II-2 Intense Competition in the Antidepressants Marketplace. II-2 Global Antidepressants Market (2004): Major Products Types of Depression and Related Disorders .II-15 Major Depressive Disorders (Major Depression).II-15 Table 1: Leading Brands in the Global Antidepressants Dysthymic Disorder (Minor Depression).II-15 Market (2001 & 2002): Sales in US$ Million for Seroxat/Paxil, Zoloft, Effexor, Cipramil/ Celexa, Wellbutrin, Prozac, Remeron, Fluoxetine Par, Serzone, and Fluoxetine Barr (include Premenstrual Dysphoric Disorder (PMDD) .II-16 corresponding Graphs/Chart) . II-4 Table 2: Leading Drugs in the Global Antidepressants Market (2003): Sales in US$ Million for Seroxat, Zoloft, Effexor, Cipramil/ Celexa, Wellbutrin, Cipralex/ Lexapro, Prozac, and Remeron (include corresponding Graphs/Chart) .II-5 Options Available in Depression Treatment .II-17 SSRI/SNRI Brands in the Global Antidepressants Market Psychotherapy or Psychiatric Consultation.II-17 (2002-2006): Sales in US$ Million by Geographic Combination of Psychotherapy and Pharmacotherapy.II-17 SSRIs Garnering Major Share of the Market. II-7 Table 3: Leading Brands in the Global SSRI Antidepressants How Can Depression Treatment become More Market (2003): Percentage Breakdown of Value Sales for Zoloft, Paxil and Paxil CR, Generic Fluoxetine, Celexa, Global Antidepressants Market: Favorable Drugs Lexapro, Prozac, Prozac Weekly, and Others (include corresponding Graphs/Chart) .II-7 Global Antidepressants Market: Unfavorable Emerging Antidepressant Classes Pose Threat to SSRI. II-8 Treatment-Resistant Depression (TRD) .II-19 2. Market Trends & Issues . II-9
New Drugs Making Way into the Market . II-9 Prozac Patent Expiry Opens Door for Generic Versions . II-9 Generic Antidepressants to Hit Market Soon . II-9 Table 4: Global Antidepressants Market (2004): Percentage Breakdown of Prevalence Rate by Disorder Type – Westerners Fight Depression Blues; Americans Depression, Anxiety, Obsessive Compulsive Disorder, Sleep Disorder, Panic Disorder, Phobias, and Others Antidepressants High in Demand but Fail to Satisfy (include corresponding Graphs/Chart) .II-20 No One is Immune: Not Even Animals!. II-11 Patent Expiry Disturbs Antidepressants Producers. II-11 Men Vs Women – Who is More Depression Prone? .II-21 Unlicensed Antidepressants Pose Danger to Depression and Smoking – Interlinked to One Another .II-22 Global Antidepressants Market (2003): Regulations 4. Product
Analysis . II-23
Governing Select Antidepressants Use in Children . II-12 What are Antidepressants? A Clear Understanding.II-23 Growing Safety Concerns – Antidepressants Under Fire . II-12 Global Antidepressants Market (2004): Select Brands ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Adverse Effects of Antidepressants and their Select Antidepressants and their Applications . II-24 Tricyclic Antidepressants (TCAs) . II-25 Global Antidepressants Market: TCA Brands and Dosage Types - Starting Dosage and Normal Dosage.II-25 Global Antidepressants Market: TCAs and their Monamine Oxidase Inhibitors (MAOIs) . II-26 Side Effects Associated with Overdose .II-38 Global Antidepressants Market: MAOI Brands and Dosage Types – Starting Dosage and Normal Dosage .II-26 Table 5: Global Antidepressants Market: Percentage Side Effects of Different MAOIs – Tranylcypromine; Breakdown of Volume Drug Consumption by Disorder Type – Depression, Generalized Anxiety Disorder, Post Traumatic Selective Serotonin Reuptake Inhibitors (SSRIs). II-27 Stress Disorder, Panic Disorder and Others (include Global Antidepressants Market: SSRIs Brands and Related corresponding Graphs/Chart) .II-39 Do Antidepressants Treat Depression Completely?.II-40 Global Antidepressants Market: Withdrawal Symptoms Global Antidepressants Market: Different SSRI Antidepressants Used for Treatment of Panic Global Antidepressants Market: SSRIs’ Off-Label A Note of Caution for Panic Patients Using Antidepressants Used for Treatment of Anxiety 5HT2 Receptor Antagonist Properties. II-32 Antidepressants: Causes For and Against.II-45 Antidepressants Effective in Curing Premenstrual Antidepressants Offer Solution for Itching and Drugs and Dosage Types - Starting Dosage Antidepressants Offer Hope for Autistic Children.II-46 Antidepressants Minimize Hot Flushes and Antidepressants’ Positive Effect on the Brain .II-47 Global Antidepressants Market: Major Drugs by Longer Duration Antidepressants Treatment Class – SSRI, SNRI, MAOI, and NaSSA. II-34 Antidepressants - A New Option for Sleep Apnea .II-47 5. Antidepressants: An In-Depth Analysis . II-35
SSRI Antidepressants May Prove Helpful in Antidepressants, a Mere Accidental Discovery. II-35 Limited Choices and High Risk Rates . II-35 Lesser Fear of Breast Cancer with Antidepressants.II-48 Better Alternatives and Wider Choice – The New Mantra II-35 Antidepressants for Reducing Chronic Back Pain .II-48 Global Antidepressants Market: Launch of Drug Types – TCAs, MAOI, SSRI, and New Generation Variants Greater Heart at Risk with Antidepressants.II-48 by Original Version, Secondary Version, Antidepressants Dissipates Sexual Drive.II-49 Hip Fractures Troubles Aged Patients .II-49 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Antidepressants can be a Deadly Prescription Table 7: World 10-Year Perspective for Antidepressants by Geographic Region – Percentage Breakdown of Dental Problems with Antidepressants. II-50 Dollar Sales for USA, Canada, Japan, Europe, Facts/Myths About Antidepressants. II-50 Asia-Pacific (excluding Japan), and Latin America Are Pregnant Women at Risk from Antidepressants? . II-50 Markets for Years 2000, 2005 & 2010 (include Is Breast Feeding Safe While on Antidepressants?. II-51 corresponding Graphs/Chart) .II-64 Homeopathic Treatment Versus Antidepressants Recent Findings on Antidepressants . II-52 III. MARKET
6. Technological
Developments . II-53
Monitoring Technology Foresees Antidepressants 1. The United States . III-1
Vagus Nerve Stimulation - Device for Treating Global Antidepressants Market: FDA Approvals Antidepressants Usage in the United States .III-1 US Antidepressants Market: Drug Usage.III-2 7. Product
Introductions/Innovations. II-54
GlaxoSmithKline Re-Introduces Paxil CR in US Market. II-54 Table 8:Leading Players in the US Antidepressants Ratiopharm Launches Ratio-Paroxetine in Canada . II-54 Market (2004 & 2005(E)): Percentage Breakdown of Value Sales for Forest Labs, GlaxoSmithKline, Apotex Releases Generic Version of Paxil. II-54 Pfizer, Wyeth, Eli Lilly and Others (include corresponding Graphs/Chart) .III-2 Table 9: Leading Players in the US SSRI/SNRI Market (2004 & 2005(E)): Percentage Breakdown of 8. Recent Industry Activity. II-56
Value Sales for Forest Labs, Pfizer, Wyeth, GlaxoSmithKline, Eli Lilly and Others Organon in Marketing Agreement with STADA. II-56 (include corresponding Graphs/Chart) .III-3 Andrx Signs Marketing Agreement with Impax and Teva . II-56 GlaxoSmithKline Collaborates with NeuroSearch . II-56 Lundbeck in Marketing Accord with Janssen-Cilag. II-56 New Drugs Set to Conquer the Market .III-4 Lundbeck Allies with Abbott Laboratories . II-57 Myriad Signs an Agreement with Abbott Laboratories . II-57 Table 10: Leading SSRI/ SNRI Brands in the US Recordati Obtains Marketing Rights from H Lundbeck . II-57 Antidepressants Market (2000-2005(E)): Percentage Breakdown of Sales for Prozac, Paxil, Zoloft, 9. Focus on Select Global Players . II-58
Celexa, Lexapro, Effexor and Others (include corresponding Graphs/Chart) . III-4 Number of SSRI/SNRI Prescriptions Dispensed in Millions (include corresponding Graphs/Chart) . III-5 Advertising Expenditure in US$ Million on Select SSRIs - Celexa (Citalopram), Prozac (Fluoxetine), Effexor XR (Venlafaxine), Zoloft (Sertraline), Organon International, Inc. (USA) . II-60 Paxil (Paroxetine), and Luvox (Fluvoxamine) (include corresponding Graphs/Chart) .III-5 Depression More Common Among Gays .III-5 FDA Inspects Suicidal Tendencies in Kids on 10. Global Market Perspective . II-63
Table 6: World Recent Past, Current & Future Analysis for Generic Drugs Pose Competition to Branded Drugs .III-7 Antidepressants by Geographic Region – USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Antidepressants Market (2001): Sales in US$ Million Figures in US$ Million for Years 2000 through 2010 for Zoloft, Paxil, Prozac & Sarafem, Celexa, and (include corresponding Graphs/Chart) .II-63 Luvox (include corresponding Graphs/Chart) .III-7 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Depression Drugs Being Used for Symptoms Other 3. Japan. III-18
US Antidepressants Market: Drugs Approved Frequent Patent Expiries – A Cause of Concern Table 18: CNS Market in Japan (2001): Sales in US$ Patent Expiry of Select Antidepressant Brands Million by Drug Class – Antidepressants, Antiulcerants, Cholesterol Reducers, Broad Antibiotic, Antiarrhythmic, Antihypertensive, Narcotic painkiller, Oral Diabetes, Oral Antihistamine, and Antiseizure (include corresponding Graphs/Chart) .III-19 Table 19: Leading Brands in the Japanese Antidepressants Market (2001 & 2002): Percentage Breakdown of Value Sales for Paxil, Luvox, Depromel, Ludiomil, Toledomin, Toledomin- Jansen, Anafranil, Tetramide, and Others (include corresponding Graphs/Chart) .III-20 Antidepressants Market in Japan – Major Drug Table 14: US Recent Past, Current & Future Analysis for Antidepressants by Product Segment – SSRI, New Generation, TCA and MAOI Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Table 20: Japanese Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 Table 15: US 10-Year Perspective for Antidepressants by (include corresponding Graphs/Chart) .III-22 Product Segment – Percentage Breakdown of Dollar Sales for SSRI, New Generation, TCA and 4. Europe. III-23
MAOI for Years 2000, 2005 & 2010 (include corresponding Graphs/Chart) .III-14 2. Canada . III-15
Table 21: Leading Players in the European Antidepressants Market (2004 & 2005(E)) – Percentage Breakdown of Value Sales for GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Wyeth and Others Increasing Use of Antidepressants among Canadian (include corresponding Graphs/Chart) .III-24 Antidepressants Market - A Recent Past Perspective .III-15 Changes in European Patent Litigation.III-24 Percentage Breakdown of Value Sales by Class – SSRI, TCAs, MOAI, and Others (include corresponding Graphs/Chart) .III-16 Table 22: European Recent Past, Current & Future Analysis for Antidepressants by Geographic Region – France, Germany, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in Warning Against Antidepressants Use in Under- US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .III-25 Table 23: European 10-Year Perspective for Antidepressants by Geographic Region – Percentage Table 17: Canadian Recent Past, Current & Future Breakdown of Dollar Sales for France, Germany, Analysis for Antidepressants: Annual Sales Figures UK, Italy, Spain, and Rest of Europe Markets for in US$ Million for Years 2000 through 2010 Years 2000, 2005 & 2010 (include corresponding (include corresponding Graphs/Chart) .III-17 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
4a. France. III-27
4f. Rest of Europe . III-35
Table 24: French Recent Past, Current & Future Analysis Focus on Select Regional Markets.III-35 for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 Danish People Display Greater Preference for (include corresponding Graphs/Chart) .III-27 4b. Germany . III-28
Table 25: German Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .III-28 4c. The United Kingdom. III-29

Table 30: Rest of Europe Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 III-34 (include corresponding Graphs/Chart) .III-36 UK Bans Antidepressant Use in Children (2003) .III-29 2000): Number of Associated Deaths in England and 5. Asia-Pacific . III-37
Wales by Drug Class – TCAs, MAOIs, SSRIs and Others (include corresponding Graphs/Chart) .III-30 A Recent Past Market Perspective .III-37 Antidepressants, a Happy Pill for Sad Scots .III-30 Table 27: UK Recent Past, Current & Future Analysis Table 31: Asia-Pacific Recent Past, Current & for Antidepressants: Annual Sales Figures in Future Analysis for Antidepressants: Annual US$ Million for Years 2000 through 2010 Sales Figures in US$ Million for Years (include corresponding Graphs/Chart) .III-32 2000 through 2010 (include corresponding Graphs/Chart) .III-38 4d. Italy . III-33

America. III-39
Table 28: Italian Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .III-33 High Usage of Antidepressants among Chileans.III-39 4e. Spain. III-34
Table 32: Latin America Recent Past, Current & Table 29: Spanish Recent Past, Current & Future Future Analysis for Antidepressants: Annual Analysis for Antidepressants: Annual Sales Figures Sales Figures in US$ Million for Years in US$ Million for Years 2000 through 2010 2000 through 2010 (include corresponding (include corresponding Graphs/Chart) .III-34 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
IV. COMPETITION
Table 52: Nine Months Sales Analysis by Product: Table 33: Half Yearly Sales Analysis: 2004-2005 (H1) 2004-2005 (Nine Months Ended, March) Table 34: Half Yearly Sales Analysis by Segment: Table 53: Annual Sales Analysis: 2003-2004 2004-2005 (H1) (In US$ million). IV-4 Table 35: Quarterly Sales Analysis: 2003-2004 Table 54: Annual Sales Analysis by Product: 2003-2004 (In US$ million) . IV-69 Table 36: Annual Sales Analysis by Segment: 7. Boehringer Ingelheim GmbH (Germany). IV-71 2003-2004 (In US$ million) . IV-4 Table 55: Annual Sales Analysis: 2003-2004 Table 37: Annual Sales Analysis by Geographical Region: 2003-2004 (In US$ million). IV-5 Table 56: Annual Sales Analysis by Product Segment: 2003-2004 (In € million) . IV-71 2. Akzo Nobel NV (The Netherlands). IV-23 Table 57: Annual Sales Analysis by Region: Table 38: First Quarter Sales Analysis: 2003-2004 (In € million) . IV-72 2004-2005 (Q1) (In € million). IV-28 8. Bristol-Myers Squibb Co. (USA) . IV-77 Table 39: First Quarter Sales Analysis by Segment: Table 58: Annual Sales Analysis: 2003-2004 2004-2005 (Q1) (In € million). IV-28 Table 40: Annual Sales Analysis: 2002-2004 Table 59: Annual Sales Analysis by Segment: 2003-2004 (In US$ billion) . IV-79 Table 41: Annual Sales Analysis by Segment: Table 60: Annual Sales Analysis by Geographic 2003-2004 (In € million). IV-28 Region: 2003-2004 (In US$ billion). IV-79 Table 42: Annual Sales Analysis by Region: 9. Cortex Pharmaceuticals, Inc. (USA) . IV-91 2003-2004 (In € million). IV-29 10. Dr. Reddy's Laboratories Ltd. (India). IV-93 Table 61: Annual Sales Analysis: 2003-2005 Organon International, Inc. (USA). IV-36 Table 62: Annual Sales Analysis by Product Segment: 2003-2004 (In INR million). IV-95 Table 43: First Quarter Sales Analysis: Table 63: Annual Sales Analysis by Geographical 2004-2005 (Q1) (In US$ million). IV-44 Region: 2003-2004 (In INR million) . IV-95 Table 44: Annual Sales Analysis: 2003-2004 Table 64: Half Yearly Sales Analysis: Table 45: Quarterly Sales Analysis: 2003-2004 2004-2005 (H1) (In US$ million). IV-99 Table 65: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million). IV-99 Table 66: Half Yearly Sales Analysis by Product: Table 46: First Quarter Sales Analysis: 2004-2005 (H1) (In US$ million). IV-99 2004-2005 (Q1) (In US$ billion). IV-56 Table 67: Annual Sales Analysis: 2002-2004 Table 47: First Quarter Sales Analysis by Geographic Region: 2004-2005 (Q1) (In US$ billion) . IV-57 Table 68: Annual Sales Analysis by Segment: Table 48: Annual Sales Analysis: 2003-2004 2003-2004 (In US$ million) . IV-100 Table 69: Annual Sales Analysis by Product: Table 49: Annual Sales Analysis by Therapy Area: 2003-2004 (In US$ million) . IV-100 2003-2004 (In US$ billion) . IV-57 Table 70: Annual Sales Analysis by Geographical Table 50: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million). IV-101 Region: 2003-2004 (In US$ billion). IV-57 Table 71: Quarterly Sales Analysis: 2003-2004 Astrazeneca Pharmaceuticals LP (USA). IV-66 Eli Lilly And Company Limited (UK) . IV-107 Table 51: Nine Months Sales Analysis: 2004-2005 (Nine months Ended, March) (In US$ million) . IV-68 Lilly Deutschland GmbH (Germany). IV-108 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Table 92: First Quarter Sales Analysis by Geographical Table 72: First Quarter Sales Analysis: Region: 2004-2005 (Q1) (In US$ billion) . IV-149 2004-2005 (Q1) (In US$ million). IV-111 Table 93: Annual Sales Analysis: 2003-2004 Table 73: Annual Sales Analysis: 2002-2004 Table 94: Annual Sales Analysis by Segment: Table 74: Quarterly Sales Analysis: 2003-2004 2003-2004 (In US$ billion) . IV-149 Table 95: Annual Sales Analysis by Geographical 13. F. Hoffmann-La Roche Ltd. (Switzerland) . IV-112 Region: 2003-2004 (In US$ billion). IV-150 Table 75: Half Yearly Sales Analysis: Table 96: Annual Sales Analysis by Quarter: 2004-2005 (H1) (In CHF million). IV-113 2003-2004 (In US$ billion) . IV-150 Table 76: Annual Sales Analysis: 2003-2004 19. Janssen-Cilag International NV (Belgium). IV-157 Table 77: Annual Sales Analysis by Division: 21. Meiji Seika Kaisha Ltd. (Japan) . IV-160 2003-2004 (In CHF millions). IV-113 Table 97: Annual Sales Analysis: 2003-2004 14. Forest Laboratories, Inc. (USA). IV-118 Table 78: First Quarter Sales Analysis: Table 98: Annual Sales Analysis by Business 2005-2006 (Q1) (In US$ billion). IV-119 Segment: 2003-2004 (In ¥ million). IV-160 Table 79: Annual Sales Analysis: 2004-2005 Table 99: Annual Sales Analysis: 2003-2004 Table 80: Quarterly Sales Analysis: 2004-2005 Table 100: Annual Sales Analysis by Segment: Table 81: Annual Sales Analysis by Geographical 2003-2004 (In US$ Million). IV-163 Region: 2004-2005 (In US$ billion). IV-120 Table 101: Quarterly Sales Analysis: 2003-2004 Table 82: Quarterly Sales Analysis: 2003-2004 23. Mylan Laboratories, Inc. (USA). IV-165 Table 83: Annual Sales Analysis by Geographical Table 102: First Quarter Sales Analysis: Region: 2003-2004 (In US$ billion). IV-120 2005-2006 (Q1) (In US$ million). IV-166 Forest Pharmaceuticals, Inc. (USA). IV-124 Table 103: Annual Sales Analysis: 2003-2005 Table 84: Half Yearly Sales Analysis: Table 104: Annual Sales Analysis by Business 2004-2005 (H1) (In £ million). IV-126 Segment: 2004-2005 (In US$ million) . IV-166 Table 85: Half Yearly Sales Analysis by Division: Table 105: Annual Sales Analysis by Product: 2004-2005 (H1) (In £ million). IV-126 2004-2005 (In US$ million) . IV-166 Table 86: Annual Sales Analysis: 2003-2004 Table 106: Quarterly Sales Analysis: 2004-2005 Table 87: Annual Sales Analysis by Division: 24. Myriad Genetics, Inc. (USA) . IV-170 2003-2004 (In £ million). IV-126 Table 107: Annual Sales Analysis: 2003-2004 (In US$ million) . IV-171 Glaxo Smithkline Canada, Inc. (Canada). IV-139 Table 108: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) . IV-171 Table 88: Annual Sales Analysis: 2002-2004 Table 89: Annual Sales Analysis by Geographical Table 109: Half Yearly Sales Analysis: Region: 2003-2004 (In DKK billion) . IV-142 2004-2005 (H1) (In US$ billion). IV-178 17. Impax Laboratories, Inc. (USA). IV-144 Table 110: Annual Sales Analysis: 2002-2004 Table 90: First Quarter Sales Analysis: Table 111: Annual Sales Analysis by Division: 2004-2005 (Q1) (In US$ billion). IV-149 2003-2004 (In US$ billion) . IV-179 Table 91: First Quarter Sales Analysis by Segment: Table 112: Annual Sales Analysis by Geographical 2004-2005 (Q1) (In US$ billion). IV-149 Region: 2003-2004 (In US$ billion). IV-179 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission ANTIDEPRESSANTS
MCP-1383
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
Table 113: Quarterly Sales Analysis: 2003-2004 Table 130: Annual Sales Analysis: 2003-2004 Sandoz Deutschland GmbH (Germany). IV-190 Table 131: Annual Sales Analysis by Region: 2003-2004 (In £ million) . IV-249 28. Orion Corporation (Finland) . IV-195 Table 114: Annual Sales Analysis: 2003-2004 Table 132: First Quarter Sales Analysis: 2004-2005 (Q1) (In € million). IV-255 29. Paddock Laboratories, Inc. (USA) . IV-198 Table 133: Annual Sales Analysis: 2003-2004 30. Par Pharmaceutical, Inc. (USA) . IV-202 Table 115: First Quarter Sales Analysis: Table 134: Annual Sales Analysis by Segment: 2004-2005 (Q1) (In US$ million). IV-202 2003-2004 (In € million) . IV-255 Solvay Pharmaceutical, Inc. (USA) . IV-263 Table 116: Annual Sales Analysis: 2003-2004 (In US$ million) . IV-203 40. STADA Arzneimittel AG (Germany) . IV-265 Table 135: First Quarter Sales Analysis: Table 117: Annual Sales Analysis by Quarter: 2004-2005 (Q1) (In € million). IV-265 2003-2004 (In US$ million) . IV-203 Table 136: First Quarter Sales Analysis by Segment: 2004-2005 (Q1) (In € million). IV-266 Table 118: Half Yearly Sales Analysis: Table 137: Annual Sales Analysis: 2003-2004 2004-2005 (H1) (In US$ billion). IV-207 Table 119: Annual Sales Analysis: 2003-2004 Table 138: Annual Sales Analysis by Segment: 2003-2004 (In € million) . IV-266 Table 120: Annual Sales Analysis by Business 41. Strides Arcolab Limited (India). IV-268 Segment: 2003-2004 (In US$ billion). IV-207 42. Temmler Pharma GmbH & Co. KG (Germany). IV-271 Table 121: Annual Sales Analysis by Geographic 43. Teva Pharmaceutical Industries Ltd. (Israel) . IV-272 Region: 2003-2004 (In US$ billion). IV-207 Table 139: Half Yearly Sales Analysis: Pfizer Australia Pty., Ltd. (Australia) . IV-221 2004-2005 (H1) (In US$ Million). IV-273 Table 140: Half Yearly Sales Analysis by Geographic Region: 2004-2005 (H1) (In US$ Million) . IV-273 Table 141: Half Yearly Sales Analysis by Business 32. Ranbaxy Pharmaceuticals, Inc. (USA). IV-229 Segment: 2004-2005 (H1) (In US$ Million). IV-274 Table 142: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ Million). IV-274 Table 122: Half-Yearly Sales Analysis: Table 143: Annual Sales Analysis by Business 2004-2005 (H1) (In € million). IV-234 Segment: 2003-2004 (In US$ Million) . IV-274 Table 123: Annual Sales Analysis: 2003-2004 44. Watson Pharmaceuticals, Inc. (USA) . IV-279 Table 144: Annual Sales Analysis: 2003-2004 Table 124: Annual Sales Analysis by Segment: 2003-2004 (In € million). IV-235 Table 145: Annual Sales Analysis by Business Segment: 2003-2004 (In US$ million). IV-280 Table 125: Annual Sales Analysis by Geographical Region: 2003-2004 (In € million). IV-235 Table 146: Half yearly Sales Analysis: 2004-2005 (H1) (In US$ million). IV-285 Table 147: Half Yearly Sales Analysis by Segment: Table 126: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million). IV-285 2004-2005 (H1) (In € million). IV-242 Table 148: Annual Sales Analysis: 2003-2004 Table 127: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In € million). IV-242 Table 149: Annual Sales Analysis by Segment: Table 128: Half Yearly Sales Analysis by Product: 2003-2004 (In US$ million) . IV-285 2004-2005 (H1) (In € million). IV-242 Table 150: Annual Sales Analysis by Region: Table 129: Annual Sales Analysis: 2003-2004 2003-2004 (In US$ million) . IV-285 Wyeth Australia Pty., Ltd. (Australia). IV-290 ANTIDEPRESSANTS - A GLOBAL STRATEGIC BUSINESS REPORT 01/06 This Report Is Protected With Digital Watermarks. Copyrights per US & ICC protocols. This Document May Not Be Printed, Copied or Distributed Outside Your Organization in Any Form Without Our Express Written Permission

Source: http://www.oic.co.kr/files/gia10043.pdf

Jpcooke_resume_srprojectmanager

J. Patrick Cooke // Sr. Project Manager Professional Experience May 2013 – September 2013 // Blast Radius / Wunderman World Health, New York, NY As a Sr. PM at Blast Radius I was responsible for the day-to-day management activities on the entire Novartis Gas-X account, as well as portions of the Novartis Prevacid account. Including but not limited to financial forecasting and budgeting

Capitolo decimo

Capitolo 10° PROFEZIA La manciata di giorni, notti, ore e minuti di fine d’anno passarono ovattati senza fare rumore; poi, allo stesso modo, in alleanza col silenzio, arrivò il mattino del trentun dicembre: il giorno di Profezia. Un giorno importante che una volta in scena viziò il silenzio e prese a fare cigolare il passaggio delle ore e dei minuti togliendo l'ovatta ai rumori e r

Copyright © 2010-2014 Medical Articles